Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
出版年份 2023 全文链接
标题
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
作者
关键词
-
出版物
BIOMEDICINE & PHARMACOTHERAPY
Volume 161, Issue -, Pages 114567
出版商
Elsevier BV
发表日期
2023-03-22
DOI
10.1016/j.biopha.2023.114567
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MMP9‐Responsive Graphene Oxide Quantum Dot‐Based Nano‐in‐Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization
- (2023) Keke Huang et al. Small
- Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
- (2022) Shinya Abe et al. Journal for ImmunoTherapy of Cancer
- Comparative assessment of early mortality risk upon immunecheckpoint inhibitors alone or in combinations with other agents across solid malignancies: a systematic review and meta-analysis
- (2022) Giuseppe Viscardi et al. EUROPEAN JOURNAL OF CANCER
- Immunomodulation of MiRNA-223-based nanoplatform for targeted therapy in retinopathy of prematurity
- (2022) Keke Huang et al. JOURNAL OF CONTROLLED RELEASE
- Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment
- (2022) Raffaele De Luca et al. EJSO
- Core Role of Hydrophobic Core of Polymeric Nanomicelle in Endosomal Escape of siRNA
- (2021) Chunhui Li et al. NANO LETTERS
- Beyond immune checkpoint blockade: emerging immunological strategies
- (2021) Shawn P. Kubli et al. NATURE REVIEWS DRUG DISCOVERY
- KRAS mutation in pancreatic cancer
- (2021) Ji Luo SEMINARS IN ONCOLOGY
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies
- (2021) Ignacio Melero et al. Nature Reviews Clinical Oncology
- GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA
- (2021) Chenwei Li et al. NUCLEIC ACIDS RESEARCH
- Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
- (2021) Alessandro Di Federico et al. Pharmaceuticals
- DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis
- (2021) Zhenxing Zhang et al. Nature Communications
- A four-chemokine signature is associated with a T cell-inflamed phenotype in primary and metastatic pancreatic cancer
- (2020) Joan Miguel Romero et al. CLINICAL CANCER RESEARCH
- EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells
- (2020) Shaorong Yu et al. ONCOGENE
- ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
- (2020) Hong Liu et al. CANCER CELL
- RNA therapeutics on the rise
- (2020) Feng Wang et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
- (2020) Muhammad Zaeem Noman et al. Science Advances
- ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression
- (2020) Meng Yuan et al. Acta Pharmaceutica Sinica B
- Immunotherapy for pancreatic cancer: A 2020 update
- (2020) Dimitrios Schizas et al. CANCER TREATMENT REVIEWS
- Challenges and Opportunities for Pancreatic Cancer Immunotherapy
- (2020) Adham S. Bear et al. CANCER CELL
- NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
- (2020) Hongwei Lv et al. Cell Metabolism
- Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities
- (2019) Vinod P. Balachandran et al. GASTROENTEROLOGY
- Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle
- (2019) Wan-Chen Cheng et al. NATURE IMMUNOLOGY
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads
- (2019) Shuyang Chen et al. Nature Communications
- Development of “CLAN” Nanomedicine for Nucleic Acid Therapeutics
- (2019) Cong‐Fei Xu et al. Small
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of EphB4-ephrin-B2 signaling reprograms the tumor immune microenvironment in head and neck cancers
- (2019) Shilpa Bhatia et al. CANCER RESEARCH
- TISIDB: an integrated repository portal for tumor-immune system interactions
- (2019) Beibei Ru et al. BIOINFORMATICS
- Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
- (2019) Han Yao et al. Nature Biomedical Engineering
- Protein palmitoylation and cancer
- (2018) Pin‐Joe Ko et al. EMBO REPORTS
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Palmitoylation stabilizes PD-L1 to promote breast tumor growth
- (2018) Yi Yang et al. CELL RESEARCH
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- Palmitoylation-dependent activation of MC1R prevents melanomagenesis
- (2017) Shuyang Chen et al. NATURE
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- SiRNA and epigenetic aberrations in ovarian cancer
- (2016) HamidReza Mirzaei et al. Journal of Cancer Research and Therapeutics
- Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
- (2016) M. Angela Aznar et al. JOURNAL OF IMMUNOLOGY
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- The zDHHC family of S-acyltransferases
- (2015) Kimon Lemonidis et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic Nras
- (2015) P Liu et al. LEUKEMIA
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Physiology of Protein S-acylation
- (2015) Luke H. Chamberlain et al. PHYSIOLOGICAL REVIEWS
- The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation
- (2015) Liang Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
- (2013) Helen Angell et al. CURRENT OPINION IN IMMUNOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
- (2012) Yuliya Pylayeva-Gupta et al. CANCER CELL
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started